rs751565055
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_001387283.1(SMARCA4):c.2059A>G(p.Lys687Glu) variant causes a missense change. The variant allele was found at a frequency of 0.00000684 in 1,461,170 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. K687N) has been classified as Uncertain significance.
Frequency
Consequence
NM_001387283.1 missense
Scores
Clinical Significance
Conservation
Publications
- Coffin-Siris syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
- intellectual disability, autosomal dominant 16Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
- rhabdoid tumor predisposition syndrome 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
- uterine corpus sarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- familial rhabdoid tumorInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SMARCA4 | ENST00000646693.2 | c.2059A>G | p.Lys687Glu | missense_variant | Exon 14 of 36 | NM_001387283.1 | ENSP00000495368.1 | |||
| SMARCA4 | ENST00000344626.10 | c.2059A>G | p.Lys687Glu | missense_variant | Exon 14 of 35 | 1 | NM_003072.5 | ENSP00000343896.4 | ||
| SMARCA4 | ENST00000643549.1 | c.2059A>G | p.Lys687Glu | missense_variant | Exon 14 of 35 | ENSP00000493975.1 | ||||
| SMARCA4 | ENST00000541122.6 | c.2059A>G | p.Lys687Glu | missense_variant | Exon 15 of 35 | 5 | ENSP00000445036.2 | |||
| SMARCA4 | ENST00000643296.1 | c.2059A>G | p.Lys687Glu | missense_variant | Exon 14 of 34 | ENSP00000496635.1 | ||||
| SMARCA4 | ENST00000644737.1 | c.2059A>G | p.Lys687Glu | missense_variant | Exon 14 of 34 | ENSP00000495548.1 | ||||
| SMARCA4 | ENST00000589677.5 | c.2059A>G | p.Lys687Glu | missense_variant | Exon 15 of 35 | 5 | ENSP00000464778.1 | |||
| SMARCA4 | ENST00000643995.1 | c.1471A>G | p.Lys491Glu | missense_variant | Exon 11 of 32 | ENSP00000496004.1 | ||||
| SMARCA4 | ENST00000644963.1 | c.703A>G | p.Lys235Glu | missense_variant | Exon 7 of 28 | ENSP00000495599.1 | ||||
| SMARCA4 | ENST00000644065.1 | c.784A>G | p.Lys262Glu | missense_variant | Exon 7 of 27 | ENSP00000493615.1 | ||||
| SMARCA4 | ENST00000642350.1 | c.544A>G | p.Lys182Glu | missense_variant | Exon 6 of 27 | ENSP00000495355.1 | ||||
| SMARCA4 | ENST00000643857.1 | c.412A>G | p.Lys138Glu | missense_variant | Exon 5 of 25 | ENSP00000494159.1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251228 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000684 AC: 10AN: 1461170Hom.: 0 Cov.: 31 AF XY: 0.00000825 AC XY: 6AN XY: 726914 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Rhabdoid tumor predisposition syndrome 2 Uncertain:2
This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 687 of the SMARCA4 protein (p.Lys687Glu). This variant is present in population databases (rs751565055, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 470278). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
Intellectual disability, autosomal dominant 16 Uncertain:1
- -
not provided Uncertain:1
In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Hereditary cancer-predisposing syndrome Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at